Home > Insider Trading > Filing (0001209191-19-060476)

Filing Details

Accession Number:: 0001209191-19-060476
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-13 17:35:50
Reporting Period:: 2019-12-12

Accepted Time:: 2019-12-13 17:35:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070494	Acadia Pharmaceuticals Inc	ACAD	Pharmaceutical Preparations (2834)	061376651

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1702283	J. Michael Yang	C/O Acadia Pharmaceuticals Inc. 3611 Valley Centre Drive, Ste. 300 San Diego CA 92130	Evp And Cco	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-12-12	22,500	$19.98	24,999	No	4	M	Direct
Common Stock	Acquisiton	2019-12-12	10,000	$21.28	34,999	No	4	M	Direct
Common Stock	Acquisiton	2019-12-12	72,979	$35.86	107,978	No	4	M	Direct
Common Stock	Disposition	2019-12-12	100,447	$44.49	7,531	No	4	S	Direct
Common Stock	Disposition	2019-12-12	5,032	$43.74	2,499	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-12-12	22,500	$0.00	22,500	$19.98
Common Stock	Stock Option (Right to Buy)	Disposition	2019-12-12	10,000	$0.00	10,000	$21.28
Common Stock	Stock Option (Right to Buy)	Disposition	2019-12-12	72,979	$0.00	72,979	$35.86

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
577,500	2028-04-17	No	4	M	Direct
30,000	2028-10-14	No	4	M	Direct
312,500	2027-03-28	No	4	M	Direct

Footnotes

Includes 876 shares of the Issuer's common stock acquired by the reporting person on November 15, 2017 pursuant to an employee stock purchase program.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.755 to $44.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.67 to $43.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the 600,000 shares originally subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments
25% of the 40,000 shares originally subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become excercisable thereafter in 36 equal monthly installments.
25% of the 400,000 shares originally subject to the stock option vested and became exercisable on March 29, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.